As of today (2024-05-01), Omeros's share price is $3.40.
Omeros's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.19. Hence, Omeros's Price-to-Free-Cash-Flow Ratio for today is 2.87.
The historical rank and industry rank for Omeros's Price-to-Free-Cash-Flow or its related term are showing as below:
OMER'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.72
Current: 2.86
During the past 13 years, Omeros's highest Price-to-Free-Cash-Flow Ratio was 4.72. The lowest was 0.00. And the median was 0.00.
OMER's Price-to-Free-Cash-Flow is ranked better than 96.7% of 212
companies
in the Biotechnology industry
Industry Median: 31.685
vs OMER: 2.86
During the past 13 years, Omeros's highest 3-Year average Free Cash Flow per Share Growth Rate was 44.00% per year. The lowest was -54.60% per year. And the median was -2.60% per year.
Omeros Price-to-Free-Cash-Flow Historical Data
The historical data trend for Omeros's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Omeros's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Omeros's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omeros's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omeros's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Omeros's Price-to-Free-Cash-Flow falls into.
Omeros Price-to-Free-Cash-Flow Calculation
Omeros's Price-to-Free-Cash-Flow ratio for today is calculated as
Omeros's Share Price of today is $3.40. Omeros's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Omeros Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Omeros's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMER has been successfully added to your 